NDC codes

FDA NDC Directory
Product NDC (as listed)83296-100Labeler and product segments. Claims need a package NDC.
Product NDC at billing width83296-0100Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
83296-100-1283296010012120 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-12)Marketed from May 21, 2024
83296-100-608329601006060 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-60)Marketed from May 21, 2024
83296-100-908329601009090 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-90)Marketed from Nov 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Xolremdi
Generic name (nonproprietary)
mavorixafor
Active ingredients
Mavorixafor — 100 mg/1
Dosage form
Capsule, Gelatin coated
Route
Oral
Labeler
X4 Pharmaceuticals, Inc.NDC labeler code 83296
Product type
Prescription drug
Marketing category
NDA — New Drug ApplicationApplication NDA 218709
Marketing start
Listing expires
Identifiers
Product ID 83296-100_26bdd232-8068-9080-e063-6394a90aa084SPL ID 26bdd232-8068-9080-e063-6394a90aa084SPL set ID 7f3a5ee3-ca73-4876-85a0-ed1e108a2237RxCUI 2684026, 2684032UNII 0G9LGB5O2W

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N483296010012 followed by a unit qualifier and the quantity

Package 83296-0100-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 83296-100

What is NDC 83296-100?
83296-100 is the product NDC for Xolremdi (mavorixafor), Mavorixafor 100 mg/1 capsule, gelatin coated, listed with the FDA by X4 Pharmaceuticals, Inc.. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Xolremdi (Mavorixafor).
What is the active ingredient?
Mavorixafor.
Who is the labeler?
X4 Pharmaceuticals, Inc., NDC labeler code 83296. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Xolremdi?
None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in